EU Regulatory Roundup, February 2019: Brexit Overwhelmingly Dominates EU Medtech Focus
With less than four weeks to go until the UK is due to leave the EU, seven of Medtech Insight's top 10 EU regulatory stories in February focused on what will happen if the UK leaves without a deal – a possibility that has been looking increasingly likely.
You may also be interested in...
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?
The European Commission has finally published detailed guidance on the EU IVDR’s classification rules. The IVDR’s completely new classification regime means guidance is urgently needed.
Do you know how to avoid the pitfalls when it comes to clinical evidence under the MDR? Or whether evidence gathered outside the US counts? Amie Smirthwaite of Maetrics answers these and other pivotal questions in this third and final part of an interview series with Medtech Insight.